Hospital
Prospect Chartercare RWMC, LLC
Prospect Chartercare RWMC, LLC was paid $57.10M by Medicaid between Jan 2018 and Dec 2024, across 215 billing codes. Its largest line is 99285, emergency room visit (most serious) — 7.4% of everything it billed.
33Billing provider infoPROSPECT CHARTERCARE RWMC, LLC
PROVIDENCE, RI 02908
PROVIDENCE, RI 02908
33aNPI1013332014assigned 02/27/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$57.10M
24GClaims382,049
24DCodes billed215
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Rhode Island
Rank by total paid#3 of 11
Median peer was paid$12.56M
This provider vs. median4.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ELDERS, ROBERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,035 | $6.14M | |
| 2019 | 70,545 | $10.59M | |
| 2020 | 34,326 | $6.36M | |
| 2021 | 46,949 | $6.13M | |
| 2022 | 53,626 | $8.31M | |
| 2023 | 65,178 | $11.46M | |
| 2024incomplete | 47,390 | $8.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.4% | 10,683 | 8,465 | $4.25M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.0% | 30,807 | 21,067 | $3.42M |
| 36415 | Collection of venous blood by venipuncture | 5.2% | 25,311 | 17,360 | $2.95M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.1% | 12,553 | 10,243 | $2.91M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.6% | 9,156 | 4,493 | $2.60M |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.2% | 16,989 | 11,453 | $2.41M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.8% | 8,499 | 7,367 | $2.15M |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.9% | 5,861 | 3,413 | $1.65M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.6% | 5,438 | 3,603 | $1.48M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.5% | 2,850 | 1,204 | $1.44M |
| 80076 | 2.1% | 7,777 | 5,966 | $1.18M | |
| 83735 | 2.0% | 6,844 | 3,701 | $1.14M |
203 more codes
| 80053 | Comprehensive metabolic panel | 1.9% | 15,642 | $1.10M |
| J1644 | Injection, heparin sodium, per 1000 units | 1.9% | 3,085 | $1.09M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 5,541 | $1.03M |
| 84100 | 1.7% | 6,203 | $969K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 5,057 | $943K |
| 81001 | 1.7% | 8,984 | $942K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 4,092 | $855K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 6,527 | $823K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 1,706 | $821K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1.4% | 2,023 | $782K |
| 84484 | 1.3% | 4,990 | $745K | |
| 83690 | 1.2% | 4,325 | $690K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.2% | 2,407 | $681K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1.2% | 2,607 | $666K |
| G0378 | Hospital observation service, per hour | 1.2% | 1,635 | $662K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 3,044 | $639K |
| 82962 | 1.1% | 3,238 | $628K | |
| 85610 | 1.1% | 5,546 | $616K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.0% | 2,348 | $598K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.0% | 4,216 | $580K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,094 | $462K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 122 | $432K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,804 | $408K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,165 | $393K |
| J3490 | Unclassified drugs | <1% | 5,880 | $392K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,066 | $379K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,840 | $369K |
| 87081 | <1% | 1,802 | $357K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,292 | $356K |
| 95806 | <1% | 496 | $353K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,508 | $340K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,826 | $304K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,338 | $301K |
| 80061 | Lipid panel | <1% | 6,094 | $288K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,511 | $284K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,240 | $281K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,095 | $275K |
| 83605 | <1% | 1,331 | $247K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,279 | $237K |
| 83880 | <1% | 1,564 | $193K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,024 | $191K |
| S9131 | Physical therapy; in the home, per diem | <1% | 1,949 | $185K |
| 81025 | <1% | 1,488 | $183K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 962 | $177K |
| 82607 | <1% | 3,514 | $174K | |
| 82947 | <1% | 1,107 | $172K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 504 | $166K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,381 | $162K |
| T1030 | Nursing care, in the home, by registered nurse, per diem | <1% | 1,270 | $157K |
| 85730 | <1% | 1,387 | $155K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,448 | $153K |
| 86141 | <1% | 2,444 | $153K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 755 | $151K |
| 82728 | <1% | 3,208 | $145K | |
| 36591 | <1% | 326 | $139K | |
| 82550 | <1% | 1,021 | $132K | |
| 83615 | <1% | 1,487 | $130K | |
| 87186 | <1% | 1,357 | $128K | |
| 86900 | <1% | 895 | $125K | |
| 82746 | <1% | 2,136 | $123K | |
| 86901 | <1% | 895 | $123K | |
| 85652 | <1% | 2,686 | $118K | |
| 86850 | <1% | 812 | $117K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 533 | $115K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 557 | $111K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 542 | $108K |
| 85045 | <1% | 1,201 | $98K | |
| 84466 | <1% | 2,116 | $96K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 149 | $93K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 571 | $89K |
| 84439 | <1% | 2,595 | $87K | |
| 83540 | <1% | 3,109 | $86K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 169 | $85K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 519 | $85K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 499 | $82K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 351 | $82K |
| 96367 | <1% | 278 | $80K | |
| 96415 | <1% | 240 | $80K | |
| 85027 | <1% | 3,219 | $78K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 639 | $75K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 813 | $73K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 813 | $73K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 586 | $73K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 7,993 | $70K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 524 | $68K |
| 87077 | <1% | 626 | $66K | |
| 84703 | <1% | 400 | $65K | |
| 85379 | <1% | 420 | $60K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,218 | $57K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 300 | $56K |
| 83721 | <1% | 147 | $52K | |
| 83013 | <1% | 436 | $51K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 368 | $49K |
| 97162 | <1% | 103 | $48K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 229 | $47K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 855 | $44K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 247 | $42K |
| 74246 | <1% | 413 | $42K | |
| 71250 | <1% | 216 | $41K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 626 | $40K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 231 | $38K |
| 80305 | <1% | 1,414 | $34K | |
| 94726 | <1% | 534 | $34K | |
| 94729 | <1% | 580 | $34K | |
| 86803 | <1% | 1,185 | $33K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 52 | $32K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 321 | $31K |
| 84207 | <1% | 608 | $27K | |
| S9097 | Home visit for wound care | <1% | 260 | $25K |
| 73030 | <1% | 150 | $24K | |
| 82150 | <1% | 200 | $24K | |
| 82565 | <1% | 1,269 | $23K | |
| 84252 | <1% | 572 | $21K | |
| 97166 | <1% | 46 | $20K | |
| S5000 | Prescription drug, generic | <1% | 430 | $19K |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 92 | $17K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 310 | $17K |
| 82803 | <1% | 93 | $17K | |
| 84425 | <1% | 792 | $16K | |
| 80353 | <1% | 274 | $16K | |
| 73630 | <1% | 245 | $16K | |
| 94060 | <1% | 180 | $15K | |
| 82043 | <1% | 1,198 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 92 | $13K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 99 | $13K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 73 | $12K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 17 | $12K |
| 84480 | <1% | 209 | $11K | |
| 71271 | <1% | 29 | $11K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 31 | $11K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 116 | $11K |
| 88313 | <1% | 134 | $10K | |
| 88342 | <1% | 209 | $10K | |
| 86480 | <1% | 145 | $10K | |
| 82652 | <1% | 148 | $10K | |
| 84590 | <1% | 428 | $9K | |
| 86592 | <1% | 175 | $9K | |
| 84520 | <1% | 335 | $9K | |
| 84460 | <1% | 986 | $7K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 179 | $7K |
| 84450 | <1% | 962 | $7K | |
| 87040 | <1% | 46 | $7K | |
| 88304 | <1% | 79 | $7K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 60 | $7K |
| 72100 | <1% | 118 | $6K | |
| 86706 | <1% | 270 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 36 | $6K |
| 86038 | <1% | 157 | $6K | |
| 73560 | <1% | 34 | $6K | |
| 84550 | <1% | 459 | $6K | |
| S9129 | Occupational therapy, in the home, per diem | <1% | 59 | $6K |
| 90715 | <1% | 13 | $5K | |
| 20610 | <1% | 27 | $5K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 33 | $5K |
| 99223 | Prolong inpt eval add15 m | <1% | 26 | $5K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 104 | $5K |
| 80050 | General health panel | <1% | 21 | $4K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 15 | $4K |
| 87340 | <1% | 213 | $4K | |
| 96523 | <1% | 81 | $4K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 30 | $4K |
| 80358 | <1% | 99 | $4K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 29 | $4K |
| 83516 | <1% | 116 | $4K | |
| 86762 | <1% | 25 | $4K | |
| 86735 | <1% | 25 | $4K | |
| 73562 | <1% | 54 | $3K | |
| 87070 | <1% | 120 | $3K | |
| 83970 | <1% | 53 | $3K | |
| 86431 | <1% | 79 | $3K | |
| 73110 | <1% | 51 | $2K | |
| 86780 | <1% | 81 | $2K | |
| 73502 | <1% | 25 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 36 | $2K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 39 | $2K |
| 74019 | <1% | 15 | $2K | |
| A4649 | Surgical supply; miscellaneous | <1% | 76 | $2K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 26 | $2K |
| 82040 | <1% | 259 | $1K | |
| 80051 | <1% | 89 | $1K | |
| A0425 | Ground mileage, per statute mile | <1% | 13 | $1K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 13 | $1K |
| 96376 | <1% | 22 | $879.08 | |
| 82140 | <1% | 20 | $878.50 | |
| 86704 | <1% | 30 | $811.47 | |
| A9150 | Non-prescription drugs | <1% | 36 | $792.41 |
| 86787 | <1% | 26 | $718.79 | |
| 86765 | <1% | 24 | $674.88 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 21 | $624.65 |
| 84165 | <1% | 25 | $580.00 | |
| 82105 | <1% | 16 | $557.35 | |
| 84154 | <1% | 16 | $496.54 | |
| 83921 | <1% | 12 | $483.35 | |
| 82784 | <1% | 13 | $465.05 | |
| 94010 | <1% | 12 | $410.86 | |
| 82785 | <1% | 14 | $391.25 | |
| 87205 | <1% | 20 | $294.89 | |
| 84481 | <1% | 14 | $232.10 | |
| 82570 | <1% | 25 | $206.95 | |
| 85018 | <1% | 23 | $177.49 | |
| 85014 | <1% | 22 | $173.92 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 32 | $99.59 |
| 83655 | <1% | 12 | $95.70 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialELDERS, ROBERT (SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Prospect Waterbury, INC. | Waterbury, CT | $84.62M |
| Prospect Manchester Hospital, INC. | Manchester, CT | $69.20M |
| Prospect CCMC, LLC | Chester, PA | $40.89M |
| Prospect CT Medical Foundation, INC. | Manchester, CT | $34.07M |
| Prospect Rockville Hospital, INC. | Vernon, CT | $30.06M |
| Prospect Chartercare Sjhsri, LLC | North Providence, RI | $10.94M |
| Prospect DCMH, LLC | Drexel Hill, PA | $10.37M |
| Prospect CCMC, LLC | Chester, PA | $5.46M |
| Alta Los Angeles Hospitals, INC. | Los Angeles, CA | $5.42M |
| Prospect CCMC, LLC | Chester, PA | $5.03M |
| Prospect CCMC, LLC | Chester, PA | $3.71M |
| Prospect Chartercare Physicians, LLC | Cranston, RI | $2.31M |
| Prospect Echn Home Health, INC. | Vernon, CT | $1.75M |
| Prospect Waterbury Home Health, INC. | Watertown, CT | $1.30M |
| Prospect Health Access Network, INC. | Chester, PA | $1.22M |
| Alta Newport Hospital, LLC | Tustin, CA | $1.16M |
| Prospect Health Access Network, INC. | Crum Lynne, PA | $924K |
| Prospect Health Access Network, INC. | Chester, PA | $872K |
| Prospect Chartercare Sjhsri, LLC | North Providence, RI | $858K |
| Prospect Health Access Network, INC. | Drexel Hill, PA | $815K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.